MarginsXMarginsX
Home › Markets › Health Care › LIMN

Liminatus Pharma Inc. (LIMN)

LIMN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.97
-0.67% on the day
Market cap
$4.0M
Nano cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerLIMN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001971387
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
9.1 months
$3.0M cash at June 30, 2026
Share count, 1 year
+148.1%
2025-10-03 to 2026-08-14
Going-concern doubt
Yes
10-Q filed August 14, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"In connection with the Company's assessment of going concern considerations in accordance with Financial Accounting Standards Board ( FASB ) ASC 205-40, Presentation of Financial Statements Going Concern , management has concluded that there is substantial doubt about its ability to continue as a going concern for one year after the date that the accompanying unaudited condensed consolidated financial statements are "
10-Q 2026-08-14
Cash and burn$3.0M cash; operating cash flow -$993K a quarter.Report 2026-06-30
Shares outstanding1,343,207 (2026-08-14); 27,064,633 a year earlier.Cover page 2026-08-14
Reverse splits, 3 years1; latest 1-for-50 on 2026-08-21Source 2026-08-21
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months5 (8-K item 3.01)8-K 2026-08-18
AuditorWithumSmith+Brown, PC, Whippany, New Jersey, United States; changed auditors 1 time in 24 months8-K 4.01 2025-05-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$1.4M-$970K$3.0M$1.4MNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$1.1M-$2.0M$1.9M$1.4MNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$8.2M-$387K$338K$1.4MNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$1.8M-$601K$725K$1.4MNeeds four quarters10-Q 2025-11-14
Q2 2025
2025-06-30
Not filed$113K-$8.8M$1.3M$1.4MNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$328K-$159K$0No debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$230K-$141K$0$20.0MNeeds four quarters10-K 2026-03-31
Q3 2024
2024-09-30
Not filed-$601K-$206KNot filedNo debt tagsNeeds four quarters10-Q 2025-11-14

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-12026-06-24
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-08-14
Latest current report
FORM 8-K
8-K2026-11-03
Latest proxyDEF 14A2026-07-13

Source: SEC EDGAR submissions feed, 109 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+17.7%
1 month-12.3%
3 months-60.1%
Year to date-90.2%
1 year-94.4%
From 52-week high-97.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
LIMNWLiminatus Pharma Inc. Warrants$0.0351

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CELZCreative Medical Technology Holdings Inc.$0.5201-1.51%$4.0M
CRISCuris Inc.$0.4358-2.07%$4.1M
BTTCBlack Titan Corporation$0.2873-9.20%$4.3M
AIMAIM ImmunoTech Inc.$0.1310-8.77%$5.2M
SNTISenti Biosciences Holdings Inc.$0.1360-2.86%$5.2M
VIVSVivoSim Labs Inc.$0.1237-2.68%$2.5M
CLDICalidi Biotherapeutics Inc.$0.6023-3.15%$2.2M
INABIN8bio Inc.$0.8160-0.49%$8.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier